2013 American Transplant Congress
Outcome in Patients Undergoing HeartMate II vs HVAD Left Ventricular Assist Device (LVAD) Implantation as a Bridge to Transplantation in Middle Aged Patients – A Single Center Experience
Objective The HeartMate II (HM II) and the HVAD are routinely used as LVADs. The aim of this study was to compare the two devices…2013 American Transplant Congress
Combined Liver, Small Bowel, Pancreas and Kidney Transplantation (LSBPKTx): Single Center Experience of over a Decade
Surgery, University of Nebraska Medical Center, Omaha, NE
BackgroundCombined liver, small bowel and pancreas transplantation (LSBPTx) is a well established treatment for patients with intestinal failure and associated liver disease. Some of these…2013 American Transplant Congress
Preliminary Experience Utilizing Boceprevir with Pegylated Interferon and Ribavirin for Treatment of Recurrent Hepatitis C Genotype 1 after Liver Transplantation
Gastroenterology and Hepatology, Mayo Clinic Arizona, Phoenix
Background Hepatitis C virus (HCV) recurrence after liver transplant is universal and causes significant reduction in both graft and patient survival. The use of protease…2013 American Transplant Congress
Excellent Liver Transplant Outcomes in Patients with Coronary Artery Disease
Aim: The aim of this study is to assess the risk factors for coronary artery disease (CAD) in patients undergoing orthotopic liver transplantation (OLT), and…2013 American Transplant Congress
Eculizumab Efficacy in aHUS Pts with Progressing TMA, with or without Prior Renal Transplant
INTRODUCTION: Ongoing aHUS post renal transplant leads to graft failure within 1 yr in 60% of patients (pts).1 Case reports suggest eculizumab (ecu) prevents ongoing…2013 American Transplant Congress
Impact of Changing Patterns in Deceased Donor Cause of Death on Organs Transplanted Per Donor
United Network for Organ Sharing, Richmond, VA
Background: The distribution of donor cause of death (DCOD) has changed substantially over the last decade. This analysis was performed to assess geographic variability and…2013 American Transplant Congress
Presence of Circulating Antibodies at the Time of Pathology Defined Antibody-Mediated Rejection after Heart Transplant: Are They out There?, The
Cedars-Sinai Heart Institute, Los Angeles, CA
BACKGROUND: The diagnosis of antibody mediated rejection (AMR) is standardized based on the ISHLT pAMR grading scale which stratifies biopsies based on the presence or…2013 American Transplant Congress
Transplant Dermatology Is an Essential Part of Transplant Care: Report of First Year Experience
Background: It has been well documented that patients who have undergone organ transplantation have a higher incidence of new skin cancers and that this risk…2013 American Transplant Congress
Impact of De Novo IgG3 DSA in Graft Survival after Liver Transplantation
Aim: To evaluate if the presence of de novo IgG3 subclass donor-specific HLA antibodies (DSA) help to identify patients at risk of graft loss after…2013 American Transplant Congress
Pathology and Clinical Progression of Biopsy Proven pAMR1 after Heart Transplantation
Cedars-Sinai Heart Institute, Los Angeles, CA
BACKGROUND: Antibody mediated rejection has now been defined as a pathology definition. The new ISHLT pathology grading scale was recently published by Barry et al.…
- « Previous Page
- 1
- …
- 105
- 106
- 107
- 108
- 109
- …
- 178
- Next Page »